Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Effekter av Lactobacillus Plantarum PS128 hos barn med ASD

14 september 2026 uppdaterad av: Chang Gung Memorial Hospital

Effekter av Lactobacillus Plantarum PS128 hos barn med autismspektrumstörning

Autism spectrum disorder (ASD) is a neurodevelopmental disorder that can cause significant social, communication and behavioral deficits. Probiotics are regarded as active microorganisms. With sufficient amounts, probiotics can regulate intestinal flora, intestinal permeability, inflammation and antioxidant reactions in the body. These reactions may further promote health, regulate metabolic disease progression and prevent complications. Lactobacillus plantarum PS128 (PS128) was reported to be a psychobiotic in several animal and human studies which modulated the levels of neurotransmitters in different brain areas. This study is to evaluate whether the consumption of PS128 can improve the symptoms of patients with ASD. The current randomized, placebo-controlled trial was conducted to investigate the psychophysiological effects of PS128 in school children with ASD.

Studieöversikt

Status

Avslutad

Studietyp

Interventionell

Inskrivning (Faktisk)

41

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Taoyuan, Taiwan
        • Chang Gung Memorial Hospital

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

7 år till 12 år (Barn)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • (1) Age 7 to 12 years old.
  • (2) PS128 group and placebo group: Children with autism spectrum disorder, confirmed by Autism Diagnostic Observation Schedule.
  • (3) Normal control group: Children without autism spectrum disorder.

Exclusion Criteria:

  • (1) Receiving antibiotics within one month.
  • (2) Probiotics used in powder, capsule, or tablet in two weeks (except for Yogurt, Yogurt, Yakult and other related foods).
  • (3) Patients with hepatobiliary gastrointestinal tract who have undergone surgery (except for hernia surgery and appendectomy)
  • (4) Those with special diets (gluten-free, casein-free, high-protein, and ketogenic diet).
  • (5) Those with a history of cancer.
  • (6) Those who are allergic to lactic acid bacteria.
  • (7) Not eligible judged by PI

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Övrig
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Fyrdubbla

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: PS128

Subjects will take PS128 capsules every day (2 capsules/day, once) for 12 weeks.

Each PS128 capsule contained >3 × 10^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg.

Placebo-jämförare: Placebo

Subjects will take placebo capsules every day (2 capsules/day, once) for 12 weeks.

The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose.

Inget ingripande: Normal control

Normal control group are enrolled by invitation from the age and gender matched healthy children.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Changes of Total Scores of Social Responsiveness Scale
Tidsram: Baseline, Week 12 and Week 16

Social Responsiveness Scale can measure the autism clinical severity with the range from 65-260. The lower scores stand for better social responsiveness.

Baseline, Week 12 and Week 16

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Changes of Total Scores of Repetitive Behavior Scale-Revised
Tidsram: Baseline, Week 12 and Week 16

Repetitive Behavior Scale-Revised is a questionnaire that focuses on repetitive behavior. The score ranges from 0-129. The lower scores stand for lower repetitive behavior.

Baseline, Week 12 and Week 16
Changes of Total Scores of Child Behavior Checklist
Tidsram: Baseline, Week 12 and Week 16

Child Behavior Checklist is a parents' report questionnaire for behavioral and emotional problems. The score ranges from 0-240. The lower scores stand for better behavioral and emotional regulation.

Baseline, Week 12 and Week 16
Changes of Total Scores of Adaptive Behavior Assessment System
Tidsram: Baseline, week 12 and Week 16

Adaptive Behavior Assessment System is a parents' report questionnaire for adaptive behavior. The score ranges from 9-171. The higher scores stand for better adaptive behavior.

Baseline, week 12 and Week 16
Changes in Accuracy of Frith-Happe Animation
Tidsram: Baseline, Week 12 and Week 16

A quick and objective test of Theory of Mind. 8 questions in total, the more correct questions stand for better Social Cognition.

Baseline, Week 12 and Week 16
Changes in Accuracy of Eyes Task
Tidsram: Baseline, Week 12 and Week 16

An advanced test for Theory of Mind. 43 questions in total, the more correct questions stand for better social skills.

Baseline, Week 12 and Week 16
Changes of Total Scores of Aberrant Behavior Checklist
Tidsram: Baseline, Week 12 and Week 16

Aberrant Behavior Checklist is a parents' report questionnaire for aberrant behavior. The score ranges from 0-174. The lower scores stand for less aberrant behavior.

Baseline, Week 12 and Week 16
Changes of Total Scores of Emotional Dysregulation Inventory
Tidsram: Baseline, Week 12 and Week 16

Emotional Dysregulation Inventory is a parents' report questionnaire for emotional dysregulation. The score ranges from 0-120. The lower scores stand for better emotional regulation.

Baseline, Week 12 and Week 16
Changes of Total Scores of Parenting Stress Index, Fourth Editon
Tidsram: Baseline, Week 12 and Week 16

Parenting Stress Index is a parents' report questionnaire for parenting stress. The score ranges from 0-180. The lower scores stand for lower parenting stress.

Baseline, Week 12 and Week 16
Assessment of Clinical Global Impression-Severity of Illness
Tidsram: Week 12 and Week 16

The Clinical Global Impression (CGI) is a clinician rated measure of illness severity, improvement, and efficacy of treatment. The CGI-I is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. The score ranges from 1-7. CGI Improvement scale: 1=very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse.

Week 12 and Week 16
Assessment of Patient Global Impression of Change
Tidsram: Week 12 and Week 16

The self-report measure Patient Global Impression of Change (PGIC) reflects a patient's belief about the efficacy of treatment. PGIC is a 7 point scale depicting a patient's rating of overall improvement. The score ranges from 1-7. Patients rate their change as "1=very much improved ," "2=much improved," "3=minimally improved," "4=no change," "5=minimally worse," "6=much worse," or "7=very much worse)."

Week 12 and Week 16
Gut Microbiota-Relative Abundance of Bifidobacterium Faecale
Tidsram: Baseline and Week 12

Collect the DNA of fecal flora to test the diversity and abundance of gut microbiota as well as short chain fatty acids in Stool samples. The 16S rRNA gene amplicons will be prepared following the Illumina protocol for preparing the 16S metagenomic sequencing library. Values represent percentages and range from 0 to 100%, with higher values indicating a higher relative abundance of the target bacterium in the gut microbiota

Baseline and Week 12
MRI T1
Tidsram: Baseline and Week 12

Brain structural volumes (cm²). The advanced processing and analysis of the MRI data have been outsourced to an external core facility. Due to resource scheduling and the prolonged timeline required for specialized image preprocessing, the data analysis is currently in progress and has not yet been finalized. Therefore, quantifiable results are unavailable for summary in the data table at this time.

Baseline and Week 12
Functional MRI (Resting-state/Biological Motion Task) - BOLD Signal
Tidsram: Baseline and Week 12

Blood-oxygen-level-dependent (BOLD) signal is a measurement used in fMRI, which reflects the neural activity. The advanced processing and analysis of the MRI data have been outsourced to an external core facility. Due to resource scheduling and the prolonged timeline required for specialized image preprocessing, the data analysis is currently in progress and has not yet been finalized. Therefore, quantifiable results are unavailable for summary in the data table at this time.

Baseline and Week 12
Diffusion Tensor Imaging (DTI) - FA
Tidsram: Baseline and Week 12

Fractional anisotropy (FA) is a measurement used in DTI, which reflects the movement of water molecules. FA ranges from 0 to 1, the higher FA value may represent more intact axons. The advanced processing and analysis of the MRI data have been outsourced to an external core facility. Due to resource scheduling and the prolonged timeline required for specialized image preprocessing, the data analysis is currently in progress and has not yet been finalized. Therefore, quantifiable results are unavailable for summary in the data table at this time.

Baseline and Week 12
Safety Assessment - Albumin
Tidsram: Baseline and Week 12

Safety is assessed function of liver and kidney such as albumin (3.5-5.4 g/dl).

Baseline and Week 12
Safety Assessment - Total Protein
Tidsram: Baseline and Week 12

Safety is assessed function of liver and kidney such as total protein (6.4-8.3 g/dl).

Baseline and Week 12
Safety Assessment - ALP
Tidsram: Baseline and Week 12

Safety is assessed function of liver and kidney such as ALP (135-320 U/L).

Baseline and Week 12
Safety Assessment - Total Bilirubin
Tidsram: Baseline and Week 12

Safety is assessed function of liver and kidney such as total bilirubin (0.3-1.2 mg/dl).

Baseline and Week 12
Safety Assessment - T-Cholesterol
Tidsram: Baseline and Week 12

Safety is assessed function of liver and kidney such as T-Cholesterol (<170 mg/dL).

Baseline and Week 12
Safety Assessment - Uric Acid
Tidsram: Baseline and Week 12

Safety is assessed function of liver and kidney such as uric acid (<7.0 mg/dl).

Baseline and Week 12
Safety Assessment - BUN
Tidsram: Baseline and Week 12

Safety is assessed function of liver and kidney such as BUN (7-25 mg/dl).

Baseline and Week 12
Safety Assessment - Creatinine
Tidsram: Baseline and Week 12

Safety is assessed function of liver and kidney such as creatinine (0.2-1.0 mg/dl).

Baseline and Week 12
Safety Assessment - AST
Tidsram: Baseline and Week 12

Safety is assessed function of liver and kidney such as AST (13-40 U/L).

Baseline and Week 12
Safety Assessment - ALT
Tidsram: Baseline and Week 12

Safety is assessed function of liver and kidney such as ALT (7-40 U/L).

Baseline and Week 12
Change in Levels of Exploratory Blood-based Biomarkers for Inflammatory Changes - MPO
Tidsram: Baseline and Week 12

Inflammatory is assessed via a composite measure of circulating cytokines - MPO (ng/mL)

Baseline and Week 12
Change in Levels of Exploratory Blood-based Biomarkers for Inflammatory Changes - IL-1β
Tidsram: Baseline and Week 12

Inflammatory is assessed via a composite measure of circulating cytokines - IL-1β (pg/mL)

Baseline and Week 12
Change in Levels of Exploratory Blood-based Biomarkers for Inflammatory Changes - TGF-β1
Tidsram: Baseline and Week 12

Inflammatory is assessed via a composite measure of circulating cytokines - TGF-β1 (pg/mL)

Baseline and Week 12
Change in Levels of Exploratory Blood-based Biomarkers for Inflammatory Changes - Eotaxin
Tidsram: Baseline and Week 12

Inflammatory is assessed via a composite measure of circulating cytokines - Eotaxin (pg/mL)

Baseline and Week 12
Change in Levels of Exploratory Blood-based Biomarkers for Inflammatory Changes - IL-6
Tidsram: Baseline and Week 12

Inflammatory is assessed via a composite measure of circulating cytokines - IL-6 (ng/mL)

Baseline and Week 12
Change in Levels of Exploratory Blood-based Biomarkers for Oxidative Stress Changes - Serotonin
Tidsram: Baseline and Week 12

Oxidative stress is assessed via Serotonin (ng/mL).

Baseline and Week 12
Change in Levels of Exploratory Blood-based Biomarkers for Oxidative Stress Changes - GABA
Tidsram: Baseline and Week 12

Oxidative stress is assessed via GABA (μmol/L).

Baseline and Week 12
Change in Levels of Exploratory Blood-based Biomarkers for Oxidative Stress Changes - Cortisol
Tidsram: Baseline and Week 12

Oxidative stress is assessed via Cortisol (6-10am 4.82-19.5, 4-8pm 2.47-11.9, μg/dl).

Baseline and Week 12
Gut Microbiota-Relative Abundance of Lactiplantibacillus Plantarum
Tidsram: Baseline and Week 12

Collect the DNA of fecal flora to test the diversity and abundance of gut microbiota as well as short chain fatty acids in Stool samples. The 16S rRNA gene amplicons will be prepared following the Illumina protocol for preparing the 16S metagenomic sequencing library. Values represent percentages and range from 0 to 100%, with higher values indicating a higher relative abundance of the target bacterium in the gut microbiota.

Baseline and Week 12

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

15 juli 2022

Primärt slutförande (Faktisk)

3 april 2024

Avslutad studie (Faktisk)

3 april 2024

Studieregistreringsdatum

Först inskickad

14 mars 2022

Först inskickad som uppfyllde QC-kriterierna

24 mars 2022

Första postat (Faktisk)

1 april 2022

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

6 oktober 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

14 september 2026

Senast verifierad

1 februari 2025

Mer information

Termer relaterade till denna studie

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera